The Differential Diagnosis of Discrepant Thyroid Function Tests: Insistent Pitfalls and Updated Flow-Chart Based on a Long-Standing Experience.

Front Endocrinol (Lausanne)

Department of Endocrine and Metabolic Diseases, Istituto Auxologico Italiano, Istituto Di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy.

Published: May 2021

Discrepant thyroid function tests (TFTs) are typical of inappropriate secretion of TSH (IST), a rare entity encompassing TSH-secreting adenomas (TSHoma) and Resistance to Thyroid Hormone (RTHβ) due to mutations. The differential diagnosis remains a clinical challenge in most of the cases. The objective of this study was to share our experience with patients presenting with discrepant TFTs outlining the main pitfalls in the differential diagnosis. medical records of 100 subjects with discrepant TFTs referred to Thyroid Endocrine Centers at the University of Milan were analyzed, retrospectively. Patients were studied by dynamic testing (TRH test, T3-suppression test, or a short course of long-acting somatostatin analog, when appropriate), sequencing, and pituitary imaging. 88 patients were correctly diagnosed as RTHβ with ( = 59; 16 men, 43 women) or without variants ( = 6; 2 men, 4 female) or TSHoma ( = 23; 9 men, 14 women). We identified 14 representative subjects with an atypical presentation or who were misdiagnosed. Seven patients, with spurious hyperthyroxinemia due to assays interference were erroneously classified as RTHβ ( = 4) or TSHoma ( = 3). Three patients with genuine TSHomas were classified as laboratory artifact ( = 2) or RTHβ ( = 1). Two TSHomas presented atypically due to coexistent primary thyroid diseases. In one RTHβ a drug-induced thyroid dysfunction was primarily assumed. These patients experienced a mean diagnostic delay of 26 ± 14 months. Analysis of the investigations which can differentiate between TSHoma and RTHβ showed highest accuracy for the T3-suppression test (100% specificity with a cut-off of TSH <0.11 μUI/ml). Pituitary MRI was negative in 6/26 TSHomas, while 11/45 RTHβ patients had small pituitary lesions, leading to unnecessary surgery in one case. Diagnostic delay and inappropriate treatments still occur in too many cases with discrepant TFTs suggestive of central hyperthyroidism. The insistent pitfalls lead to a significant waste of resources. We propose a revised flow-chart for the differential diagnosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7358450PMC
http://dx.doi.org/10.3389/fendo.2020.00432DOI Listing

Publication Analysis

Top Keywords

differential diagnosis
12
discrepant thyroid
8
thyroid function
8
function tests
8
discrepant tfts
8
t3-suppression test
8
men women
8
thyroid
6
rthβ
6
patients
6

Similar Publications

Prevalence of Hepatozoon canis infection in dogs from the area of Lublin Voivodship.

Pol J Vet Sci

June 2024

Department of Epizootiology and Clinic of Infectious Diseases, Faculty of Veterinary Medicine, University of Life Sciences in Lublin, 30 Głęboka Street, 20-612 Lublin, Poland.

Canine hepatozoonosis is a tick-borne protozoal disease. Two species of Hepatozoon may infect dogs: Hepatozoon americanum and H. canis.

View Article and Find Full Text PDF

A 2-year-old female Assam Hill goat was presented with a clinical history of anorexia, fever, mild anemia, rough body coat, dehydration, tachycardia, dyspnea and swelling of palpable lymph nodes. Hematology revealed low hemoglobin, packed cell volume, red blood cell and thrombocyte count. Biochemical analysis showed increased serum concentration of alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine and urea in comparison to the normal reference range.

View Article and Find Full Text PDF

In patients presenting with post-malarial anemia following intravenous artesunate treatment, post-artesunate delayed hemolysis should be considered in the differential diagnosis, even in endemic settings. Close monitoring for signs of delayed hemolysis in patients previously treated with intravenous artesunate for severe malaria, regardless of their malaria exposure history or geographic location is crucial.

View Article and Find Full Text PDF

Biomarker potential of plasma cell-free DNA for cholangiocarcinoma.

Heliyon

December 2024

Research Group in Multidimensional Health and Disease (MHD), Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, 12120, Thailand.

Background: To prevent the development of cholangiocarcinoma, an effective screening opisthorchiasis viverrini and/or differential diagnosis of and the cholangiocarcinoma is crucial needed. The level and quality of cfDNA in plasma are being investigated for their potential role as biomarkers in cholangiocarcinoma.

Methods: The study enrolled 43 healthy controls (N), 36 -infected subjects (OV), and 36 cholangiocarcinoma patients (CCA).

View Article and Find Full Text PDF

Motivation: Proteins at the cell surface connect signaling networks and largely determine a cell's capacity to communicate and interact with its environment. In particular, variations in transcriptomic profiles are often observed between healthy and diseased cells, leading to distinct sets of cell-surface proteins. For these reasons, cell-surface proteins may act as biomarkers for the detection of cells of interest in tissues or body fluids, are often the target of pharmaceutical agents, and hold significant promise in the clinical practice for diagnosis, prognosis, treatment development, and evaluation of therapy response.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!